Mallinckrodt (NYSE:MNK) – Equities researchers at Oppenheimer issued their Q2 2018 earnings per share (EPS) estimates for Mallinckrodt in a research note issued to investors on Tuesday, May 15th. Oppenheimer analyst C. Liu forecasts that the company will earn $1.37 per share for the quarter. Oppenheimer has a “Hold” rating on the stock. Oppenheimer also issued estimates for Mallinckrodt’s Q3 2018 earnings at $1.74 EPS, Q4 2018 earnings at $1.75 EPS, FY2018 earnings at $6.18 EPS, FY2019 earnings at $6.68 EPS, FY2020 earnings at $7.51 EPS, FY2021 earnings at $6.01 EPS and FY2022 earnings at $5.94 EPS.

Mallinckrodt (NYSE:MNK) last released its earnings results on Tuesday, May 8th. The company reported $1.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.23. The firm had revenue of $572.60 million during the quarter, compared to analysts’ expectations of $568.78 million. Mallinckrodt had a net margin of 57.56% and a return on equity of 11.59%. Mallinckrodt’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.04 EPS.

Several other analysts have also recently commented on the stock. Morgan Stanley lowered their target price on shares of Mallinckrodt from $27.00 to $14.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 9th. Barclays set a $12.00 price objective on shares of Mallinckrodt and gave the company an “underweight” rating in a research note on Wednesday, May 9th. Canaccord Genuity set a $14.00 price objective on shares of Mallinckrodt and gave the company a “hold” rating in a research note on Tuesday, May 8th. Cantor Fitzgerald reissued a “buy” rating and set a $42.00 price objective on shares of Mallinckrodt in a research note on Tuesday, May 8th. Finally, Wells Fargo set a $15.00 price objective on shares of Mallinckrodt and gave the company a “hold” rating in a research note on Friday, May 4th. Three research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $31.26.

MNK stock opened at $16.07 on Friday. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of 2.18, a PEG ratio of 0.36 and a beta of 1.13. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.10 and a quick ratio of 1.90. Mallinckrodt has a one year low of $14.84 and a one year high of $15.96.

Large investors have recently bought and sold shares of the stock. State of Alaska Department of Revenue acquired a new position in shares of Mallinckrodt during the 4th quarter valued at $129,000. Victory Capital Management Inc. acquired a new position in shares of Mallinckrodt during the 1st quarter valued at $104,000. Amundi Pioneer Asset Management Inc. acquired a new position in shares of Mallinckrodt during the 4th quarter valued at $190,000. Sciencast Management LP acquired a new position in shares of Mallinckrodt during the 4th quarter valued at $210,000. Finally, CIBC World Markets Inc. acquired a new position in shares of Mallinckrodt during the 4th quarter valued at $231,000.

In related news, insider James E. Flynn sold 312,928 shares of Mallinckrodt stock in a transaction on Wednesday, May 9th. The shares were sold at an average price of $13.39, for a total transaction of $4,190,105.92. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.80% of the company’s stock.

About Mallinckrodt

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.

Earnings History and Estimates for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.